{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:00:36Z","timestamp":1792130436792,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Cagliari","id":[{"id":"https:\/\/ror.org\/003109y17","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To provide an updated and critical overview of the available clinical evidence on the use of faricimab for the treatment of macular edema secondary to retinal vein occlusion (RVO), with particular focus on efficacy, durability of response, and clinical applicability in both trial and real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed and Scopus databases. Pivotal phase III randomized clinical trials and real-world studies evaluating intravitreal faricimab in patients with branch, central, or hemiretinal vein occlusion were included. Both treatment-na\u00efve and previously treated eyes were considered. Evidence was qualitatively synthesized with attention to visual and anatomical outcomes, treatment durability, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from the BALATON and COMINO phase III trials demonstrated that faricimab achieved visual and anatomical outcomes comparable to aflibercept 2.0\u00a0mg during fixed monthly dosing, with maintenance of efficacy up to 72 weeks under treat-and-extend regimens. A clinically meaningful proportion of patients achieved extended treatment intervals, suggesting potential reduction in treatment burden. Real-world studies largely confirmed consistent anatomical efficacy across different RVO subtypes and clinical scenarios. However, functional improvement was more heterogeneous, particularly in chronic or therapy-resistant cases, where anatomical and visual outcomes were frequently dissociated, likely reflecting irreversible retinal ischemia or structural damage. Across studies, faricimab showed a generally favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Available evidence supports faricimab as an effective and well-tolerated therapeutic option for RVO-related macular edema, especially when initiated early in the disease course. However, although extended dosing intervals were achieved in a proportion of patients, superiority in durability compared with other anti-VEGF agents has not yet been demonstrated. Further prospective, comparative, and long-term real-world studies are needed to better define patient selection criteria and the optimal positioning of faricimab within current RVO treatment algorithms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07304-2","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:19:21Z","timestamp":1781047161000},"page":"2989-3003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Faricimab: current evidence for the treatment of retinal vein occlusion"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7867-3342","authenticated-orcid":false,"given":"Livio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":false,"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-6366","authenticated-orcid":false,"given":"Giulia","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1728-6098","authenticated-orcid":false,"given":"Flavia","family":"Chiosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0956-4925","authenticated-orcid":false,"given":"Filippo","family":"Lixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-014X","authenticated-orcid":false,"given":"Mario","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-5000","authenticated-orcid":false,"given":"Eleonora","family":"D\u2019Aniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-0555","authenticated-orcid":false,"given":"Claudio","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"7304_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott IU, Campochiaro PA, Newman NJ, Biousse V (2020) Retinal vascular occlusions. Lancet 396:1927\u20131940. https:\/\/doi.org\/10.1016\/s0140-6736(20)31559-2","journal-title":"Lancet"},{"key":"7304_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"RL RogersS, McIntosh","year":"2010","unstructured":"RogersS, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium (2010) The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313\u2013319. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"key":"7304_CR3","doi-asserted-by":"publisher","first-page":"100964","DOI":"10.1016\/j.preteyeres.2021.100964","volume":"85","author":"SS Hayreh","year":"2021","unstructured":"Hayreh SS (2021) Photocoagulation for retinal vein occlusion. Prog Retin Eye Res 85:100964. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100964","journal-title":"Prog Retin Eye Res"},{"key":"7304_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.preteyeres.2004.12.001","volume":"24","author":"SS Hayreh","year":"2005","unstructured":"Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24:493\u2013519. https:\/\/doi.org\/10.1016\/j.preteyeres.2004.12.001","journal-title":"Prog Retin Eye Res"},{"key":"7304_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/tomography9050139","volume":"9","author":"L Vitiello","year":"2023","unstructured":"Vitiello L, Salerno G, Coppola A, Abbinante G, Gagliardi V, Pellegrino A (2023) Simultaneous Branch Retinal Artery and Central Retinal Vein Occlusion Improved with No Ocular Therapy: A Case Report. Tomography 9:1745\u20131754. https:\/\/doi.org\/10.3390\/tomography9050139","journal-title":"Tomography"},{"key":"7304_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s40123-023-00677-1","volume":"12","author":"D Kazantzis","year":"2023","unstructured":"Kazantzis D, Sergentanis TN, Machairoudia G, Dimitriou E, Kroupis C, Theodossiadis G, Theodossiadis P, Chatziralli I (2023) Correlation Between Imaging Morphological Findings and Laboratory Biomarkers in Patients with Retinal Vein Occlusion. Ophthalmol Ther 12:1239\u20131249. https:\/\/doi.org\/10.1007\/s40123-023-00677-1","journal-title":"Ophthalmol Ther"},{"key":"7304_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/apo.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH et al (2023) Update on Retinal Vein Occlusion. Asia-Pac J Ophthalmol 12:196\u2013210. https:\/\/doi.org\/10.1097\/apo.0000000000000598","journal-title":"Asia-Pac J Ophthalmol"},{"key":"7304_CR8","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/diagnostics13091620","volume":"13","author":"CJT Ong","year":"2023","unstructured":"Ong CJT, Wong MYZ, Cheong KX, Zhao J, Teo KYC, Tan TE (2023) Optical Coherence Tomography Angiography in Retinal Vascular Disorders. Diagnostics 13:1620. https:\/\/doi.org\/10.3390\/diagnostics13091620","journal-title":"Diagnostics"},{"key":"7304_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12886-022-02415-w","volume":"22","author":"V Castro-Navarro","year":"2022","unstructured":"Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, Montero-Hern\u00e1ndez J, Cervera-Taulet E (2022) Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant. BMC Ophthalmol 22:191. https:\/\/doi.org\/10.1186\/s12886-022-02415-w","journal-title":"BMC Ophthalmol"},{"key":"7304_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY (2010) Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology 117:1094\u20131101e5. https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.058","journal-title":"Ophthalmology"},{"key":"7304_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology 117:1113\u20131123e15. https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.060","journal-title":"Ophthalmology"},{"key":"7304_CR12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"A Hang","year":"2023","unstructured":"Hang A, Feldman S, Amin AP, Ochoa JAR, Park SS (2023) Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals 16:1140. https:\/\/doi.org\/10.3390\/ph16081140","journal-title":"Pharmaceuticals"},{"key":"7304_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/opth.s7631","volume":"4","author":"N Karia","year":"2010","unstructured":"Karia N (2010) Retinal vein occlusion: Pathophysiology and treatment options. Clin Ophthalmol 4:809\u2013816. https:\/\/doi.org\/10.2147\/opth.s7631","journal-title":"Clin Ophthalmol"},{"key":"7304_CR14","doi-asserted-by":"publisher","first-page":"104496","DOI":"10.1016\/j.drudis.2025.104496","volume":"30","author":"J Le Du","year":"2025","unstructured":"Le Du J, Ronco C (2025) Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges. Drug Discov Today 30:104496. https:\/\/doi.org\/10.1016\/j.drudis.2025.104496","journal-title":"Drug Discov Today"},{"key":"7304_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","volume":"70","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM (2025) Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials. Surv Ophthalmol 70:1067\u20131089. https:\/\/doi.org\/10.1016\/j.survophthal.2025.05.008","journal-title":"Surv Ophthalmol"},{"key":"7304_CR16","doi-asserted-by":"publisher","unstructured":"Nicula C, Nicula D, Rednik A, Bulboaca A, Cri\u0219an O (2020) Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up. J Ophthalmol 2020(6830148). https:\/\/doi.org\/10.1155\/2020\/6830148","DOI":"10.1155\/2020\/6830148"},{"key":"7304_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/pharmaceutics12080703","volume":"12","author":"C Iovino","year":"2020","unstructured":"Iovino C, Mastropasqua R, Lupidi M et al (2020) Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature. Pharmaceutics 12:703. https:\/\/doi.org\/10.3390\/pharmaceutics12080703","journal-title":"Pharmaceutics"},{"key":"7304_CR18","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.3390\/jcm13175006","volume":"13","author":"L Vitiello","year":"2024","unstructured":"Vitiello L, Lixi F, Coppola A, Abbinante G, Gagliardi V, Salerno G, De Pascale I, Pellegrino A, Giannaccare G (2024) Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature. J Clin Med 13:5006. https:\/\/doi.org\/10.3390\/jcm13175006","journal-title":"J Clin Med"},{"key":"7304_CR19","doi-asserted-by":"publisher","first-page":"176691","DOI":"10.1016\/j.ejphar.2024.176691","volume":"976","author":"A Kuriyama","year":"2024","unstructured":"Kuriyama A, Nakamura S, Inokuchi Y, Abe H, Yasuda H, Hidaka Y, Nagaoka K, Soeda T, Shimazawa M, Hara H (2024) The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice. Eur J Pharmacol 976:176691. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176691","journal-title":"Eur J Pharmacol"},{"key":"7304_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M, Faricimab (2022) First Approval. Drugs 82:825\u2013830. https:\/\/doi.org\/10.1007\/s40265-022-01713-3","journal-title":"Drugs"},{"key":"7304_CR21","unstructured":"Faricimab (Vabysmo) (2025) Indication: for the treatment of macular edema secondary to retinal vein occlusion: reimbursement recommendation. Available online at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK613790\/. Accessed\u00a0 24\u00a0Sept 2025"},{"key":"7304_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251400508","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Barbosa M, Pannatier Schuetz Y, Castro DG, Nascimbeni AC, Barry MP, Ambresin A (2025) Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in na\u00efve neovascular age-related macular degeneration. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721251400508","journal-title":"Eur J Ophthalmol"},{"key":"7304_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251407415","author":"E Borrelli","year":"2025","unstructured":"Borrelli E, Reibaldi M (2025) The importance of imaging biomarkers for predicting outcomes in neovascular AMD. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721251407415","journal-title":"Eur J Ophthalmol"},{"key":"7304_CR24","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1038\/s41433-025-03997-7","volume":"39","author":"E Borrelli","year":"2025","unstructured":"Borrelli E, Boscia F, Lanzetta P, Lupidi M, Mastropasqua R, Nicol\u00f2 M, Parravano M, Ricci F, Staurenghi G, Vadal\u00e0 M, Viola F, Vujosevic S, Bandello F (2025) Intravitreal faricimab for diabetic macular oedema and neovascular age-related macular degeneration: general considerations and practical recommendations by an expert panel of Italian retina specialists. Eye (Lond) 39:3005\u20133014. https:\/\/doi.org\/10.1038\/s41433-025-03997-7","journal-title":"Eye (Lond)"},{"key":"7304_CR25","doi-asserted-by":"publisher","unstructured":"Panos GD, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku WM (2023) Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies. Drug Des Devel Ther 2023 17:2861\u20132873. https:\/\/doi.org\/10.2147\/dddt.s427416","DOI":"10.2147\/dddt.s427416"},{"key":"7304_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14728222.2022.2036121","volume":"26","author":"L Ferro Desideri","year":"2022","unstructured":"Ferro Desideri L, Traverso CE, Nicol\u00f2 M (2022) The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. Expert Opin Ther Targets 26:145\u2013154. https:\/\/doi.org\/10.1080\/14728222.2022.2036121","journal-title":"Expert Opin Ther Targets"},{"key":"7304_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicol\u00f2","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE (2021) Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs 30:193\u2013200. https:\/\/doi.org\/10.1080\/13543784.2021.1879791","journal-title":"Expert Opin Investig Drugs"},{"key":"7304_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","volume":"28","author":"RM Hussain","year":"2019","unstructured":"Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (2019) Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs 28:861\u2013869. https:\/\/doi.org\/10.1080\/13543784.2019.1667333","journal-title":"Expert Opin Investig Drugs"},{"key":"7304_CR29","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J (2022) Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci 23:9424. https:\/\/doi.org\/10.3390\/ijms23169424","journal-title":"Int J Mol Sci"},{"key":"7304_CR30","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/opth.s231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP (2021) Angiopoietins as Potential Targets in Management of Retinal Disease. Clin Ophthalmol 15:3747\u20133755. https:\/\/doi.org\/10.2147\/opth.s231801","journal-title":"Clin Ophthalmol"},{"key":"7304_CR31","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"7304_CR32","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P, Basu K, Danzig CJ, Guymer R, Haskova Z, Heier JS, Kotecha A, Liu Y, Loewenstein A, Seres A, Willis JR, Wykoff CC, Paris LP (2023) BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. Ophthalmol Sci 3:100302. https:\/\/doi.org\/10.1016\/j.xops.2023.100302","journal-title":"Ophthalmol Sci"},{"key":"7304_CR33","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH, BALATON and COMINO Investigators (2024) Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology 131:950\u2013960. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"key":"7304_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG, BALATON and COMINO Investigators (2025) Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmol Retina 9:848\u2013859. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005","journal-title":"Ophthalmol Retina"},{"key":"7304_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC, YOSEMITE, Investigators RHINE (2024) Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 131:708\u2013723. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"7304_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R, TENAYA, Investigators LUCERNE (2024) TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 131:914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"7304_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-025-01254-8","author":"T Hikichi","year":"2025","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y (2025) Six-month comparative outcomes of aflibercept and faricimab in treatment-na\u00efve macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-025-01254-8","journal-title":"Jpn J Ophthalmol"},{"key":"7304_CR38","doi-asserted-by":"publisher","first-page":"e0335015","DOI":"10.1371\/journal.pone.0335015","volume":"20","author":"M Kondo","year":"2025","unstructured":"Kondo M, Shimura M, Tsujikawa A, Muraoka Y, Kogo T, Akiyama Y, Hama Y, Tsujimura J, Iwasaki K, Kamei M (2025) A multicenter, single-arm study using a modified faricimab treat-and-extend regimen in patients with macular edema due to central retinal vein occlusion: RVOSTAR study design protocol. PLoS ONE 20:e0335015. https:\/\/doi.org\/10.1371\/journal.pone.0335015","journal-title":"PLoS ONE"},{"key":"7304_CR39","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2147\/opth.s521384","volume":"19","author":"V Agrawal","year":"2025","unstructured":"Agrawal V, Gupta A, Agrawal V, Sheth JU (2025) Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study). Clin Ophthalmol 19:1855\u20131862. https:\/\/doi.org\/10.2147\/opth.s521384","journal-title":"Clin Ophthalmol"},{"key":"7304_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","volume":"11","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, Nakagawa T, Hara F, Nochi Y, Yamamoto S, Hiratsuka Y, Nakao S (2025) Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retina Vitreous 11:79. https:\/\/doi.org\/10.1186\/s40942-025-00703-3","journal-title":"Int J Retina Vitreous"},{"key":"7304_CR41","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.2147\/opth.s549896","volume":"19","author":"S Inokuchi","year":"2025","unstructured":"Inokuchi S, Mizuki Y, Kamata A, Onishi J, Hayashi T, Mizuki N (2025) Real-World Efficacy of Intravitreal Faricimab for Macular Edema Secondary to Retinal Vein Occlusion: Short-Term Outcomes and Optical Coherence Tomography Biomarker Analysis. Clin Ophthalmol 19:3669\u20133679. https:\/\/doi.org\/10.2147\/opth.s549896","journal-title":"Clin Ophthalmol"},{"key":"7304_CR42","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/jcm14072454","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, Asani B, Ansch\u00fctz A, Eckardt F, Priglinger SG, Schiefelbein J (2025) Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. J Clin Med 14:2454. https:\/\/doi.org\/10.3390\/jcm14072454","journal-title":"J Clin Med"},{"key":"7304_CR43","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.3390\/jcm14207197","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, Eckardt F, Asani B, Priglinger SG, Schiefelbein J (2025) Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results. J Clin Med 14:7197. https:\/\/doi.org\/10.3390\/jcm14207197","journal-title":"J Clin Med"},{"key":"7304_CR44","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s10384-025-01237-9","volume":"69","author":"T Hikichi","year":"2025","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y (2025) Short\u2013term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion. Jpn J Ophthalmol 69:918\u2013925. https:\/\/doi.org\/10.1007\/s10384-025-01237-9","journal-title":"Jpn J Ophthalmol"},{"key":"7304_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10792-025-03836-4","volume":"45","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhao M, Miao H, Qi H (2025) Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China. Int Ophthalmol 45:463. https:\/\/doi.org\/10.1007\/s10792-025-03836-4","journal-title":"Int Ophthalmol"},{"key":"7304_CR46","doi-asserted-by":"publisher","first-page":"102475","DOI":"10.1016\/j.ajoc.2025.102475","volume":"40","author":"J Hanson","year":"2025","unstructured":"Hanson J, Yamamoto M, Tsui E, Tsui I (2025) Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema. Am J Ophthalmol Case Rep 40:102475. https:\/\/doi.org\/10.1016\/j.ajoc.2025.102475","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"7304_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10384-025-01254-8","volume":"70","author":"T Hikichi","year":"2026","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y (2026) Six-month comparative outcomes of aflibercept and faricimab in treatment-na\u00efve macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol 70(1):117\u2013122. https:\/\/doi.org\/10.1007\/s10384-025-01254-8","journal-title":"Jpn J Ophthalmol"},{"key":"7304_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-026-00804-7","author":"L Wu","year":"2026","unstructured":"Wu L, Rojas S, Rao X, Politis M, Roca JA, Nehemy M, Berrocal MH, Fromow-Guerra J, Barraza-Lino K, Lopez C, Maia M, Cardenas-Mir\u00f3n A, Gabela G, Baldivieso-Hurtado O, Gabela C, Chinchilla L, Verdaguer JI, Zas M, Young M, Garc\u00eda-Aguirre G, Ramirez-Estudillo JA, Abreu N, Flores M, Velez W, Baez Y, Arriola-Lopez A, Casella AM (2026) Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group. Int J Retina Vitreous. https:\/\/doi.org\/10.1186\/s40942-026-00804-7","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"7304_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12886-026-04695-y","volume":"26","author":"A Kilani","year":"2026","unstructured":"Kilani A, Assaf A, Vogt D, Vounotrypidis E, Parlak M, Jochem C, Wolf A (2026) Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study. BMC Ophthalmol 26(1):114. https:\/\/doi.org\/10.1186\/s12886-026-04695-y","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"7304_CR50","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40123-026-01338-9","volume":"15","author":"A \u00c7ak\u0131r","year":"2026","unstructured":"\u00c7ak\u0131r A, Akkan F, Kapran Z, \u00dcnal M, \u015eerif N, Uzundede T, Karata\u015f G, \u00d6zt\u00fcrk M, D\u00fcndar H, Erakg\u00fcn T, Alp MN, Ko\u00e7ak N, Saatci AO, \u00c7etin EN, Durukan AH, \u015eahin M, Muhacir F, Ye\u015filta\u015f S, Uyar OM, Emre S, \u015eekero\u011flu MA, \u00d6nen M, Bulut M, Karalezli A, Kaday\u0131f\u00e7\u0131lar S, \u00d6zdek \u015e, Do\u011fanay S, Kaya M, \u00d6z \u00d6, Kaderli ST, Avc\u0131 R, \u015eermet F, Demirel S, K\u00fc\u00e7\u00fckerd\u00f6nmez C, Y\u0131ld\u0131r\u0131m C, \u0130pek \u015eC, Ayhan Z, Altan T, G\u00fcrelik \u0130G, G\u00f6rg\u00fcn E, Yenerel NM, Seymeno\u011flu G, Vural E, S\u00fcl S, \u00c7\u0131t\u0131r\u0131k M, \u00d6zdemir HB, C\u00f6merter D, Karaba\u015f VL, \u00d6zdemir H (2026) Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study. Ophthalmol Ther 15(3):1165\u20131177. https:\/\/doi.org\/10.1007\/s40123-026-01338-9","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"7304_CR51","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1102\u20131112e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021","journal-title":"Ophthalmology"},{"issue":"6","key":"7304_CR52","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124\u20131133e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022","journal-title":"Ophthalmology"},{"issue":"5","key":"7304_CR53","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","volume":"119","author":"D Boyer","year":"2012","unstructured":"Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA (2012) Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 119(5):1024\u20131032. https:\/\/doi.org\/10.1016\/j.ophtha.2012.01.042","journal-title":"Ophthalmology"},{"issue":"3","key":"7304_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278\u2013284. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-301504","journal-title":"Br J Ophthalmol"},{"key":"7304_CR55","doi-asserted-by":"publisher","first-page":"e950495","DOI":"10.12659\/ajcr.950495","volume":"26","author":"H Sano","year":"2025","unstructured":"Sano H, Yanai R, Mitamura Y (2025) Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report. Am J Case Rep 26:e950495. https:\/\/doi.org\/10.12659\/ajcr.950495","journal-title":"Am J Case Rep"},{"key":"7304_CR56","doi-asserted-by":"publisher","first-page":"e91170","DOI":"10.7759\/cureus.91170","volume":"17","author":"H Hirai","year":"2025","unstructured":"Hirai H, Yasuda S, Imoto S, Tsujinaka H, Kase S (2025) Central Retinal Artery Occlusion After Intravitreal Injection of Faricimab: A Case Report. Cureus 17:e91170. https:\/\/doi.org\/10.7759\/cureus.91170","journal-title":"Cureus"},{"key":"7304_CR57","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1177\/11206721241306225","volume":"35","author":"HM Le","year":"2025","unstructured":"Le HM, Querques G, Guenoun S, El Ghazi D, Haddad WM, Mouallem A, Semoun O, Souied EH (2025) Acute intra ocular inflammation following intravitreal injections of faricimab: A multicentric case series. Eur J Ophthalmol 35:1358\u20131365. https:\/\/doi.org\/10.1177\/11206721241306225","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"7304_CR58","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/13696998.2025.2478755","volume":"28","author":"Y Yanagi","year":"2025","unstructured":"Yanagi Y, Tsujimura J, Ohno S, Higashi K, Sakashita N, Shoji A, Igarashi A (2025) Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan. J Med Econ 28(1):448\u2013459. https:\/\/doi.org\/10.1080\/13696998.2025.2478755","journal-title":"J Med Econ"},{"key":"7304_CR59","doi-asserted-by":"publisher","unstructured":"Baljoon A, Diaby V, Suther S, Dutton M, Ali A, Eljilany I (2026) Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States. https:\/\/doi.org\/10.1007\/s41669-026-00643-0. Pharmacoecon Open","DOI":"10.1007\/s41669-026-00643-0"},{"key":"7304_CR60","doi-asserted-by":"publisher","unstructured":"Shi F, Tan S, Shu Y, Liu T, Xia Y, Buehrer C, Han S (2026) Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. J Comp Eff Res e 250190. https:\/\/doi.org\/10.57264\/cer-2025-0190","DOI":"10.57264\/cer-2025-0190"},{"issue":"1","key":"7304_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.36469\/001c.129832","volume":"12","author":"D Samac\u00e1-Samac\u00e1","year":"2025","unstructured":"Samac\u00e1-Samac\u00e1 D, Robles A, Ocampo H, Rodr\u00edguez FJ, Sardi-Correa C, Prieto-Pinto L, B\u00fchrer C, Tamayo C, Rodr\u00edguez D, Hern\u00e1ndez-Quintana M (2025) Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia. J Health Econ Outcomes Res 12(1):97\u2013105. https:\/\/doi.org\/10.36469\/001c.129832","journal-title":"J Health Econ Outcomes Res"},{"issue":"3","key":"7304_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s41669-023-00465-4","volume":"8","author":"C B\u00fchrer","year":"2024","unstructured":"B\u00fchrer C, Paling T, Gale R, Paulo T, Bagijn M (2024) Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis. Pharmacoecon Open 8(3):445\u2013457. https:\/\/doi.org\/10.1007\/s41669-023-00465-4","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"7304_CR63","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4103\/tjo.tjo_17_20","volume":"11","author":"K Spooner","year":"2020","unstructured":"Spooner K, Fraser-Bell S, Hong T, Chang A (2020) Optical-coherence tomography angiography and ultrawide-field angiography findings in eyes with refractory macular edema secondary to retinal vein occlusion switched to aflibercept: A subanalysis from a 48-week prospective study. Taiwan J Ophthalmol 11(4):352\u2013358. https:\/\/doi.org\/10.4103\/tjo.tjo_17_20","journal-title":"Taiwan J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07304-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:02:40Z","timestamp":1791208960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07304-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7304"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07304-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enrico Borelli - although the co-author is an editorial board member of the journal, there was no involvement with the peer review process for this article. Other authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}